GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Market Cap

Brainstorm Cell Therapeutics (FRA:GHDN) Market Cap : €33.54 Mil (As of May. 20, 2024)


View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Brainstorm Cell Therapeutics's share price for the quarter that ended in Mar. 2024 was €0.515. Brainstorm Cell Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 68.34 Mil. Therefore, Brainstorm Cell Therapeutics's market cap for the quarter that ended in Mar. 2024 was €35.20 Mil.

Brainstorm Cell Therapeutics's quarterly market cap increased from Sep. 2023 (€8.34 Mil) to Dec. 2023 (€13.91 Mil) and increased from Dec. 2023 (€13.91 Mil) to Mar. 2024 (€35.20 Mil).

Brainstorm Cell Therapeutics's annual market cap declined from Dec. 2021 (€125.95 Mil) to Dec. 2022 (€50.40 Mil) and declined from Dec. 2022 (€50.40 Mil) to Dec. 2023 (€13.91 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Brainstorm Cell Therapeutics's Enterprise Value for Today is €33.85 Mil.


Brainstorm Cell Therapeutics Market Cap Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Market Cap Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.43 135.01 125.95 50.40 13.91

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.34 75.31 8.34 13.91 35.20

Competitive Comparison of Brainstorm Cell Therapeutics's Market Cap

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Market Cap falls into.



Brainstorm Cell Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Brainstorm Cell Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€0.23*60.4892
=€13.91

Brainstorm Cell Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=€0.515*68.3419
=€35.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brainstorm Cell Therapeutics  (FRA:GHDN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Brainstorm Cell Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (FRA:GHDN) Headlines

No Headlines